HC Wainwright Comments on Alpha Cognition Q1 Earnings

Posted by Lorenzo Tanos on Mar 20th, 2025

Alpha Cognition, Inc. (NASDAQ:ACOG – Free Report) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Alpha Cognition in a research note issued on Tuesday, March 18th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.72) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Alpha Cognition’s Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.02) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.67) EPS.

Alpha Cognition Price Performance

NASDAQ:ACOG opened at $5.70 on Thursday. Alpha Cognition has a 52 week low of $4.66 and a 52 week high of $7.00. The company’s 50 day moving average price is $5.92. The stock has a market capitalization of $91.31 million, a PE ratio of -2.23 and a beta of 2.50.

Institutional Investors Weigh In On Alpha Cognition

A number of hedge funds and other institutional investors have recently bought and sold shares of ACOG. National Bank of Canada FI purchased a new stake in Alpha Cognition during the fourth quarter valued at approximately $69,000. Manatuck Hill Partners LLC purchased a new stake in Alpha Cognition during the fourth quarter valued at approximately $395,000. Tudor Investment Corp ET AL purchased a new stake in Alpha Cognition during the fourth quarter valued at approximately $412,000. MYDA Advisors LLC purchased a new stake in Alpha Cognition during the fourth quarter valued at approximately $589,000. Finally, Bleichroeder LP purchased a new stake in Alpha Cognition during the fourth quarter valued at approximately $1,024,000.

Alpha Cognition Company Profile

(Get Free Report)

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.